Shilpa Medicare has received establishment inspection report (EIR), from United States Food and Drug Administration (USFDA). The company has received of EIR for both API manufacturing...
Shilpa Medicare has received Form no 483 observations, related to SEZ formulation facilities situated at Jadcherla, Telangana, from the United States Food & Drug Administration (USFDA)....
The US health regulator has issued an Establishment Inspection Report (EIR) to Shilpa Medicare for its manufacturing facilities located at Raichur in Karnataka. Shilpa Medicare...